Covid-19 vaccine - GeoVax Labs
Alternative Names: GEO-CM01; GEO-CM02; SARS-COV-2 vaccine - GeoVax Labs; Wuhan coronavirus (2019-nCoV) vaccine - GeoVax LabsLatest Information Update: 30 Jan 2025
At a glance
- Originator GeoVax Labs
- Class COVID-19 vaccines; DNA vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 30 Jan 2025 Preclinical development is ongoing in USA (GeoVax Labs pipeline, January 2025)
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA
- 20 Sep 2023 Pharmacodynamics data from a preclinical study in COVID-2019 infections (Prevention) released by GeoVax Labs